Brokerages Set Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Price Target at $8.00

Shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) have been given a consensus rating of “Hold” by the six research firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $8.00.

MIST has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. Zacks Research cut Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. Wall Street Zen lowered Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, January 10th. Finally, Wells Fargo & Company upped their target price on Milestone Pharmaceuticals from $4.00 to $8.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th.

Milestone Pharmaceuticals Trading Down 3.9%

Shares of MIST opened at $1.71 on Thursday. The firm has a market capitalization of $145.64 million, a price-to-earnings ratio of -2.09 and a beta of 0.48. The company has a debt-to-equity ratio of 2.74, a current ratio of 8.24 and a quick ratio of 8.24. Milestone Pharmaceuticals has a 1-year low of $0.63 and a 1-year high of $3.06. The company has a 50-day moving average of $1.86 and a 200 day moving average of $2.00.

Insider Transactions at Milestone Pharmaceuticals

In related news, insider Lorenz Muller sold 53,566 shares of Milestone Pharmaceuticals stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $2.32, for a total value of $124,273.12. Following the completion of the sale, the insider directly owned 196,486 shares in the company, valued at $455,847.52. The trade was a 21.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO Jeffrey Edward Nelson sold 58,007 shares of the company’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $2.32, for a total transaction of $134,576.24. Following the completion of the sale, the chief operating officer directly owned 41,993 shares of the company’s stock, valued at approximately $97,423.76. This trade represents a 58.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 416,327 shares of company stock valued at $935,458. Insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several hedge funds have recently modified their holdings of the business. Sapient Capital LLC purchased a new position in Milestone Pharmaceuticals during the third quarter valued at approximately $25,000. Strategic Family Wealth Counselors L.L.C. purchased a new stake in Milestone Pharmaceuticals during the fourth quarter worth $25,000. Eaton Financial Holdings Company LLC bought a new stake in Milestone Pharmaceuticals during the 4th quarter valued at $26,000. Bank of America Corp DE boosted its position in Milestone Pharmaceuticals by 200,550.0% during the 3rd quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock valued at $32,000 after acquiring an additional 16,044 shares in the last quarter. Finally, Stephenson & Company Inc. purchased a new position in shares of Milestone Pharmaceuticals in the 3rd quarter valued at $40,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.